Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF‐platform compounds.
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors and BioInvent International AB, a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat cancer, announce the extension of their collaboration to co-develop multi-functional oncolytic viruses (OV) encoding for undisclosed antibodies sequences capable of treating a broad range of solid tumors.
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B financing.
Thermo Fisher Scientific has agreed to acquire viral vector contract development and manufacturing organization (CDMO), Brammer Bio, for around $1.7bn in cash.
Imago BioSciences, a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, has announced a $40 million Series B financing led by Omega Funds, an international investment firm that creates and invests in life sciences companies.
Merck and NGM Biopharmaceuticals announced that Merck has exercised its option to extend the research phase of the companies’ broad, strategic collaboration for an additional two-year period from March 2020 to March 2022.
US pharmaceutical company Pfizer has secured an exclusive option to acquire gene therapy firm Vivet Therapeutics in a deal that could be valued at around €560m ($635.8m).
German biotech company Evotec has entered into a partnership with The Global Antibiotic Research and Development Partnership (GARDP) to discover antibiotics for the treatment of drug-resistant bacterial infections.
Ono Pharmaceutical and twoXAR have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease.
Imara, a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD) and other hemoglobinopathies, announced the closing of an oversubscribed $63 million Series B cross-over financing.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.